FDA approves Pimjetmi after a 56% response rate in Phase 3 TGCT testing, giving Merck KGaA a new once-daily rare-tumour treatment.
Immunome's varegacestat enters EMA review after strong RINGSIDE results, but safety, competition and approval remain key uncertainties.
Merck KGaA has agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value, offering $20 per ADS. The transaction centers on divesiran, an RNA interference therapy that achieved an 88% response rate in Phase 2 polycythemia vera testing.
Amphista begins its 54-patient AMX-883 Phase 1 trial in AML and high-risk MDS. Examine the novel BRD9 mechanism, safety tests and next milestones.
Bio-Techne shareholders have approved Merck KGaA’s $11.3 billion cash acquisition, clearing a major hurdle in a transaction designed to expand the German group across multi-omics, spatial biology, precision diagnostics and cell therapy workflows.
Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.
Find out how Abbisko’s TGCT drug pimicotinib just crossed a major milestone with the FDA—and what this means for patients and the CSF-1R class.